DISTURBANCES OF LIPID-METABOLISM IN CHILDREN WITH CHRONIC-RENAL-FAILURE

被引：23

作者：

QUERFELD, U

机构：

[1] University Children's Hospital, University of Cologne, Cologne, 50924

来源：

PEDIATRIC NEPHROLOGY | 1993年 / 7卷 / 06期

关键词：

CHRONIC RENAL FAILURE; LIPOPROTEIN METABOLISM; ATHEROSCLEROSIS;

D O I：

10.1007/BF01213345

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

This review discusses the pathogenesis, clinical significance and current therapy of hyperlipoproteinaemia (HLP) in children with chronic renal failure. Uraemic dyslipidaemia, characterized by hypertriglyceridaemia and low high-density lipoprotein-cholesterol levels, is present in the majority patients with chronic renal failure. In addition, serum levels of total cholesterol, very low-density lipoprotein-cholesterol, low-density lipoprotein-cholesterol and apolipoprotein B are frequently elevated. The pathophysiological mechanisms causing these disturbances are complex and mainly involve a diminished catabolism of triglyceride-rich lipoproteins. For unknown reasons and independent of other lipoproteins, serum levels of the highly atherogenic and thrombogenic lipoprotein(a) are also often elevated. HLP is an important factor in cardiovascular morbidity and mortality. In addition, dyslipidaemia may enhance progression of renal disease in patients with residual renal function. Therefore, treatment of HLP seems indicated in overtly hyperlipidaemic patients, but until there is more experience with lipid lowering drugs in children, no safe recommendations for pharmacological treatment of HLP can be given. Dietary modifications can be recommended only to a limited extent.

引用

页码：749 / 757

页数：9

共 107 条

[1]

Wynder E., Coronary artery disease prevention: cholesterol, a pediatric perspective, Prev Med, 18, pp. 323-409, (1989)

[2]

Avram M.M., Topics in nephrology: The Long Island College Hospital — role of cholesterol and lipids in renal disease, Am J Med, 87, (1989)

[3]

D'Amico G., Sanna G., Lipid abnormalities in renal disease, Kidney Int, 39, pp. S1-S72, (1991)

[4]

Berger M., James G.P., Davis E.R., Jasper P.M., Brouhard B.H., Travis L.B., Cunningham R.J., Hyperlipidemia in uremic children: response to peritoneal dialysis and hemodialysis, Clin Nephrol, 9, pp. 19-24, (1978)

[5]

Papadopoulou Z.L., Sandler P., Tina L.U., Jose P.A., Calcagno P.L., Hyperlipidemia in children with chronic renal insufficiency, Pediatr Res, 15, pp. 887-891, (1981)

[6]

Asayama K., Ito H., Nakahara C., Hasegawa A., Kato K., Lipid profiles and lipase activities in children and adolescents with chronic renal failure treated conservatively or with hemodialysis or transplantation, Pediatr Res, 18, pp. 783-788, (1984)

[7]

Zacchello G., Pagnan A., Sidran M.P., Ziron L., Braggion M., Pavanello L., Facchin P., Further definition of lipid lipoprotein abnormalities in children with various degrees of chronic renal insufficiency, Pediatr Res, 21, pp. 462-465, (1987)

[8]

Massry S.G., Lipid abnormalities, renal failure, and parathyroid hormone, Am J Med, 87, pp. 42N-44N, (1989)

[9]

Querfeld U., Salusky I.B., Nelson P., Foley J., Fine R.N., Hyperlipidemia in pediatric patients undergoing peritoneal dialysis, Pediatr Nephrol, 2, pp. 447-452, (1988)

[10]

Plasma lipid distributions in selected North American populations: The Lipid Research Clinics Program Prevalence Study, Circulation, 60, pp. 427-439, (1979)

← 1 2 3 4 5 6 7 8 9 10 →